Product innovation will help asthma sufferers and save NHS money Friday 30 November 2007 PDF Print Bedfont Scientific announce the launch of a major new product to aid in the management of asthma. The hand-held monitor uses new technology and will improve the lives of asthma sufferers while saving the NHS prescription costs. The company have just been awarded a local prize for innovation. Gas analysis specialists Bedfont received the prize at the Medway Business Awards on the 15th November after announcing its newest project – the NObreath. New technology has been used to create an innovative and affordable monitor that measures levels of nitric oxide (NO) on a patient’s breath. The monitor allows a patient’s asthma to be better managed with inhaled steroids, improving symptom control and quality of life. The NHS will also make savings on prescription costs by ensuring correct dosages are prescribed and steroid regimes are complied with. A marker for airway inflammation, exhaled NO measurements indicate slight changes in the patient’s physiology, alerting asthma specialists even before the onset of symptoms. The NObreath has been developed alongside advances in electro-chemical sensor technology, making breath NO monitoring accessible to a wider audience of health professionals than ever before. Technical manager Phil Bromley said “This is a much anticipated new product for Bedfont. The way we have used this new technology will make breath NO monitoring available to a far greater population of asthma sufferers.” It is reported that 5.2 million people in the UK suffer from asthma, costing the NHS £889 million per year. A study has shown that the cost of treating an asthma attack in hospital is over 3.5 times more than treating well-controlled asthma.* The NObreath will be available from Bedfont early in 2008. NOTE TO EDITORS *Information taken from Where do we stand? Asthma in the UK today, 2004, Asthma UK, http://www.asthma.org.uk/health_professionals/ordering_mater... accessed 29.11.07 Bedfont Scientific is based in Rochester, Kent. Bedfont is already well established within the respiratory field as world leaders in the support of smoking cessation programmes, using breath carbon monoxide monitors. Their breath gas monitors, also including those for carbon monoxide poisoning, gastroenterology and inhaled nitric oxide therapy, are sold in every continent. For more information, please contact Jennifer Cole on 01634 673739 or email Jennifer@bedfont.com This press release was distributed by ResponseSource Press Release Wire on behalf of Bedfont Scientific in the following categories: Health, Medical & Pharmaceutical, for more information visit http://pressreleasewire.responsesource.com/about.